| Abstract [eng] |
Crohn's disease is a chronic inflammatory bowel disease characterized by an unpredictable clinical course and various manifestations. Perianal involvement, a severe form of the disease that affects approximately one-fifth of patients, often causes debilitating symptoms and a significant reduction in quality of life. Extraintestinal manifestations further increase the burden of the disease, highlighting its systemic nature. The treatment of Crohn's disease poses great challenges in order to achieve long-term remission of the disease, avoid complications, and reduce the frequency of relapses. This case report presents a complex case of a young man with perianal Crohn's disease complicated by extraintestinal lesions, treatment resistance, drug side effects and complications. The patient was treated with ustekinumab, a monoclonal antibody against interleukin 12/23, and achieved deep and sustained remission of Crohn's disease. This case illustrates the potential role of ustekinumab as a promising treatment for refractory Crohn's disease, highlights the complexity of managing severe Crohn's disease, and the importance of a multidisciplinary approach in optimizing patient treatment outcomes and quality of life. |
